ESR1 and metastatic neoplasm: While treatment with selective ER modulators (SERMs) such as Tamoxifen; ER degraders (SERDs); and aromatase inhibitors (AI) have successfully improved disease prognosis in this subtype, approximately 40% of patients acquire resistance to these endocrine therapies and succumb to metastatic disease [5,6,7,8].